“Baby, baby, baby what will it be?” —Prince

John DeFlice |
John Deflice, myeloma patient, with backdrop of ASH conference in Orlando 2019

With so many great studies covered at ASH 2019, what will take home the honors for the best outstanding oral presentation? Will it be a Chimeric Antigen Receptor (CAR) or Bispecific T-cell Engager (BiTEs) trials, or will it be a new four-drug combination trial? How about one study that has a 100% response rate in myeloma patients? That alone sounds incredible!

A potential trial with a low profile of side effects as controllable cytokine release syndrome (CRS) and almost no neurological effects. This trial is for patients who have had 5 to 18 failed therapies and demonstrate persistent active disease. These patients have a poor response to immunomodulators, proteasome inhibitors, and to anti-CD38 infusion, confirming a relapsed/refractory state. This sounds incredible for a study that has an equal number of males and females who were triple- and penta-refractory to various therapies. Dr. Deepu Madduri presented a multi-center CAR-T Cell trial, JNJ-4528, containing two antibodies directed at BCMA on the myeloma cell. This study has shown a high overall response, and patients in the study expanded their T-cells; these T-cells maintain a longer memory.

My choice for the most important oral presentation would be the CARTITUDE-1 study. Aside from my fondness for the name, how could one argue with the results? I am anxious to know the results of the phase II and phase III studies to which patients are currently enrolled. I am very interested to know what’s in store for these patients over time. Clearly, I am not the only one impressed with these results as the FDA has recently given JNJ-4528 “BREAKTHROUGH” status.

One Response to "“Baby, baby, baby what will it be?” —Prince"
  1. Thanks a lot for sharing this with all of us you really know what you are talking about! Bookmarked. Kindly also visit my site =). We could have a link exchange agreement between us!

Comments are closed.